Literature DB >> 15853723

C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences.

Joseph F Bower1, Kelly L Sanders, Ted M Ross.   

Abstract

DNA vaccinations effectively induce both humoral and cellular immune responses to immunogens from diverse infectious agents. However, DNA vaccines expressing the HIV-1 envelope glycoprotein (Env) are poorly immunogenic when expressed from wild-type (wt) DNA sequences. Two recent approaches used to enhance the immunogenicity of Env expressed from a DNA vaccine are the fusion of the molecular adjuvant, C3d, to a soluble form of Env and the use of codon-optimized (co) env gene inserts. Independently, each approach enhances antibody titer and cellular responses against Env expressed from gene inserts. The goal of this study was to examine if both codon-optimization of env gene inserts and C3d conjugation to Env could function in a synergistic manner to enhance immunogenicity. Mice (BALB/c) were inoculated with decreasing doses (2.0 microg, 0.2 microg or 0.02 microg) of co DNA expressing Env alone or fused to three copies of murine C3d (mC3d3) gene. Mice vaccinated with the highest dose (2.0 microg) of DNA had high anti-Env specific antibody titers regardless of the addition of mC3d3. At lower doses (0.2 microg and 0.02 microg) of DNA, mice vaccinated with Env-mC3d3 had enhanced immune responses compared to mice vaccinated with DNA expressing Env only. In addition, mice vaccinated with Env-mC3d3 at the highest doses of DNA had enhanced interleukin-4 secreting cells, while mice vaccinated with the lowest dose of DNA had enhanced interferon-gamma secreting cells. Therefore, both codon-optimization of env sequences and C3d conjugation to Env appear to enhance anti-Env antibodies in an independent and additive manner.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15853723      PMCID: PMC1266284          DOI: 10.2174/1570162053506937

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  41 in total

1.  Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression.

Authors:  Karen M Haas; Franklin R Toapanta; Julie A Oliver; Jonathan C Poe; John H Weis; David R Karp; Joseph F Bower; Ted M Ross; Thomas F Tedder
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

2.  DNA immunization with a bovine rotavirus VP4 gene induces a Th1-like immune response in mice.

Authors:  S Suradhat; D Yoo; L A Babiuk; P Griebel; M E Baca-Estrada
Journal:  Viral Immunol       Date:  1997       Impact factor: 2.257

3.  Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage.

Authors:  S André; B Seed; J Eberle; W Schraut; A Bültmann; J Haas
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

4.  Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity.

Authors:  K S Cole; J L Rowles; B A Jagerski; M Murphey-Corb; T Unangst; J E Clements; J Robinson; M S Wyand; R C Desrosiers; R C Montelaro
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

Review 5.  Candidate AIDS vaccines.

Authors:  B S Graham; P F Wright
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

6.  HIV-1 Env glycoproteins from two series of primary isolates: replication phenotype and immunogenicity.

Authors:  F Mustafa; J F Richmond; R Fernandez-Larsson; S Lu; R Fredriksson; E M Fenyö; M O'Connell; E Johnson; J Weng; J C Santoro; H L Robinson
Journal:  Virology       Date:  1997-03-03       Impact factor: 3.616

7.  Codon usage limitation in the expression of HIV-1 envelope glycoprotein.

Authors:  J Haas; E C Park; B Seed
Journal:  Curr Biol       Date:  1996-03-01       Impact factor: 10.834

8.  DNA immunization with plasmids expressing hCGbeta-chimeras.

Authors:  Nadia Terrazzini; Sólveig Hannesdóttir; Peter J Delves; Torben Lund
Journal:  Vaccine       Date:  2004-06-02       Impact factor: 3.641

9.  DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.

Authors:  Joseph F Bower; Thomas D Green; Ted M Ross
Journal:  Virology       Date:  2004-10-25       Impact factor: 3.616

10.  C3d of complement as a molecular adjuvant: bridging innate and acquired immunity.

Authors:  P W Dempsey; M E Allison; S Akkaraju; C C Goodnow; D T Fearon
Journal:  Science       Date:  1996-01-19       Impact factor: 47.728

View more
  11 in total

Review 1.  Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity.

Authors:  Franklin R Toapanta; Ted M Ross
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

2.  Fusion to chicken C3d enhances the immunogenicity of the M2 protein of avian influenza virus.

Authors:  Zhenhua Zhang; Yongqing Li; Shufang Xu; Fuyong Chen; Li Zhang; Beiyu Jiang; Xiaoling Chen
Journal:  Virol J       Date:  2010-05-09       Impact factor: 4.099

3.  Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice.

Authors:  Matthew D Dunn; Shannan L Rossi; Donald M Carter; Matthew R Vogt; Erin Mehlhop; Michael S Diamond; Ted M Ross
Journal:  Virol J       Date:  2010-05-12       Impact factor: 4.099

4.  Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus.

Authors:  Nitin Bhardwaj; Mark T Heise; Ted M Ross
Journal:  PLoS Negl Trop Dis       Date:  2010-06-22

5.  C3d adjuvant activity is reduced by altering residues involved in the electronegative binding of C3d to CR2.

Authors:  Franklin R Toapanta; Dilhari R DeAlmeida; Matthew D Dunn; Ted M Ross
Journal:  Immunol Lett       Date:  2010-01-12       Impact factor: 3.685

6.  Breaching peripheral tolerance promotes the production of HIV-1-neutralizing antibodies.

Authors:  Kristin M S Schroeder; Amanda Agazio; Pamela J Strauch; Sean T Jones; Scott B Thompson; Michael S Harper; Roberta Pelanda; Mario L Santiago; Raul M Torres
Journal:  J Exp Med       Date:  2017-07-11       Impact factor: 14.307

7.  The MSHA strain of Pseudomonas aeruginosa activated TLR pathway and enhanced HIV-1 DNA vaccine immunoreactivity.

Authors:  Jue Hou; Yong Liu; Ying Liu; Yiming Shao
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

8.  A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.

Authors:  Ted M Ross; Kutub Mahmood; Corey J Crevar; Kirsten Schneider-Ohrum; Penny M Heaton; Rick A Bright
Journal:  PLoS One       Date:  2009-06-24       Impact factor: 3.240

9.  Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle.

Authors:  Rick A Bright; Donald M Carter; Corey J Crevar; Franklin R Toapanta; Jonathan D Steckbeck; Kelly S Cole; Niranjan M Kumar; Peter Pushko; Gale Smith; Terrence M Tumpey; Ted M Ross
Journal:  PLoS One       Date:  2008-01-30       Impact factor: 3.240

10.  Enhanced immunogenicity of HIV-1 envelope gp140 proteins fused to APRIL.

Authors:  Gözde Isik; Kwinten Sliepen; Thijs van Montfort; Rogier W Sanders
Journal:  PLoS One       Date:  2014-09-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.